About David Seftel, MD:
David Seftel, M.D., M.B.A. is CEO and Chief Medical Officer of Enable Biosciences, a multi-award winning early and accurate disease diagnosis company based in South San Francisco, CA. Since inception in 2015, Enable has been awarded 10 grants from agencies including the National Institutes of Health, the National Science Foundation and the Juvenile Diabetes Research Fund and won the HBS New Venture Competition for the region in 2016. Enable’s researchers have also been supported by the Gates Foundation at Stanford. Enable is currently developing an improved rapid COVID-19 test with it’s public health laboratory partners. Dr. Seftel also serves as an Immunology research panel reviewer for the National Institutes of Health. He is currently the Principal Investigator for two additional research projects sponsored by the NIH/National Institutes of Allergy and Infectious Disease dealing with the development of ultrasensitive and highly specific diagnostic tests for a variety of difficult-to-detect diseases like Lyme disease and pediatric allergies. A Harvard Business School graduate, he did his clinical training at Harvard’s Beth Israel-Deaconess Hospital, Penn State and Loyola University of Chicago and served as a Co-Investigator in the landmark Stanford-JDRF-Enable Biosciences Type 1 Diabetes Assay Performance study.
Organized by Shannon Lundgren HBS ’94
-Latest numbers – who, where and how bad, macro and micro (local)
-Governors guidance initiative guest : Fred Brown, HBS 1985
-Serology / Antibody Testing – testing trial participation update